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Abstract
Background: Hepatitis C virus (HCV) is mainly transmitted by parenteral route, being blood transfusion and
intravenous drug use the most frequent risk factors. However, it has been suggested that there are other routes of
transmission. There are several studies where HCV RNA has been detected in saliva of patients infected with HCV,
and epidemiological studies have proposed the dental treatments as possible risk factors for HCV transmission. The
purpose of this study was to detect the presence of HCV RNA in saliva of patients with active infection and
associating with periodontal or liver disease.
Methods: Patients with quantifiable HCV-RNA in serum were enrolled in the study. Periodontal disease was
assessed using the modified gingival index (MGI). Presence of dental plaque was assessed with the use of disclosing
tablets. Patients were clinically and laboratory evaluated to identify the stage of liver disease, the HCV RNA was
determinate in saliva by nested RT-PCR. To determine associations between different parameters univariate and
multivariate analysis were used.
Results: A total of 45 patients were included. Of these patients, 21 (46.6%) had hepatitis, 23 (51.1%) had cirrhosis
and one patient (2.4%) presented hepatocellular carcinoma (HCC). Viral loads in serum ranged from 2.31–6.68 log
IU/ml with a mean of 5.46 log IU/ml (95% CI 5.23–5.70). HCV RNA was positive in saliva of 29 patients (64.4%) and
was not detected in 16 (35.6%). For univariate analysis three independent variables were associated with the
detection of HCV-RNA in saliva: gender, viral load and dental plaque and multivariate analysis only one independent
variable viral load >5.17 log IU/mL remained significantly associated with the detection of HCV in saliva (p = 0.0002).
A statistical difference was observed when viral load was analyzed, log 5.85 IU/mL (95% CI 5.67–6.02) for patients
with HCV in saliva vs. log 4.77 IU/mL (95% CI 4.35–5.19) for patients without HCV in saliva (p = 0.0001). The detection
of HCV-RNA in saliva was more frequent in patients with relatively high serum viral loads.
Conclusion: HCV-RNA in saliva was associated with the level of serum viral load but not with periodontal or liver
disease severity.
Keywords: Periodontal disease, Viral load, Gingivitis prevalence, Risk factors, Liver disease severity
* Correspondence: sosajurado@hotmail.com; gerardo.santos.lopez@gmail.com
1Laboratorio de Biología Molecular y Virología, Centro de Investigación
Biomédica de Oriente, Instituto Mexicano del Seguro Social, Km 4.5 Carretera
Federal Atlixco-Metepec, Metepec, Puebla CP 74360, México
Full list of author information is available at the end of the article
© 2014 Sosa-Jurado et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited.
Sosa-Jurado et al. BMC Infectious Diseases 2014, 14:72
http://www.biomedcentral.com/1471-2334/14/72
Background
Hepatitis C virus (HCV) infection is an important public
health concern with an estimated 160 million persons
(prevalence ~2.35%) infected worldwide [1]. HCV is the
causative agent of chronic hepatitis, cirrhosis, and hepa-
tocellular carcinoma (HCC). Thus, HCV causes 27% and
25% of all cirrhosis and HCC cases, respectively [2].
HCV is mainly transmitted by parenteral route, and
the more frequent risk factors are blood transfusion be-
fore the availability of tests to donors screening and in-
travenous drug use. HCV transmission is also associated
with other risk factors including unprotected sexual prac-
tices, multiple sex partners, tattooing, piercing and history
of either surgery or intra-familial hepatitis [3].
Frequent diagnosis of HCV infection in patients with-
out any parenteral risk factor suggests the existence of
other transmission routes [4]. At respect, HCV RNA has
been detected in the saliva of HCV-infected patients,
[5-8] and epidemiological studies proposed dental treat-
ment is another probable risk factor.
A contributing factor for transmission of HCV in
saliva is the presence of periodontal disease [9]. Accor-
dingly, severe gingivitis is characterized by a constant
bleeding accompanied by an increased secretion of gin-
gival crevicular fluid (GCF), which may be potential sour-
ces of HCV [5] and the salivary glands [10-12]
Gingivitis prevalence reaches 84% in adult males [13]
and 54% in females [14] in some regions of Mexico.
Therefore, in the present work we determined the pres-
ence of viral RNA in saliva samples of a group of pa-
tients with active hepatitis C in order to identify whether
detection of salivary HCV is associated with the pres-
ence of periodontal disease, severity of liver disease, or
the amount of viral RNA in peripheral blood.
Methods
Patients
Forty-five patients who received medical care at the
Gastroenterology Service of the High Specialty Medical
Unit of Mexican Institute for Social Security in Puebla,
Mexico were enrolled in the study. Inclusion criteria
were patients of both genders, age range 18–70 years, ab-
normal alanine aminotransferase (ALT) levels, positive to
anti-HCV antibodies and detectable HCV RNA in serum
(viral load >1.77 log IU/ml). Patients were clinically and
laboratory evaluated to identify stage of liver disease. As
part of the diagnostic procedures, prothrombin time and
platelet counts were performed. An epidemiological ques-
tionnaire was applied to evaluate risk factors, and written
informed consent was obtained from each participant.
Patients co-infected with human immunodeficiency
virus (HIV) and/or hepatitis B virus (HBV), patients who
had undergone antiviral treatment, edentate patients and
those with oral ulcers were excluded from the study.
The study was performed following ethical regulations
approved by Local Research and Health Ethics Commit-
tee #2101 of Mexican Institute Social Security (Protocol:
R-2008-2101-10) and in accordance with the Declaration
of Helsinki.
The sample size (n) was calculated according to Her-
nandez Samperi et al., 2010 [15], using the formula: n =
(n’/(1 + n’/N)), where n’ is calculated as s2/V2, s2 = p
(1- p) and V2 is the square of standard error, while N is
the number of patients without treatment; p is the
prevalence (%) calculated in previous studies reporting
the positivity to HCV in saliva [5,7]. The substitution in
this formula was carried out with the following values:
N = 80, se = 0.05, and p = 0.3.
Measurement of modified gingival index
Periodontal status was evaluated using the Modified
Gingival Index (MGI). Results were reported as healthy
(0 to < 0.1), mild (0.1 to < 1.0), moderate (1.0 – 2.0) and
severe (> 2.0) [16,17].
Determination of dental plaque
In order to assess the amount of dental plaque, disclos-
ing tablets were used to stain the teeth. Tooth pigmenta-
tion was then compared with a dental chart and results
were reported as good < 20%, Acceptable 20% – 40%, and
poor > 40% [18].
Sample collection and RNA extraction in saliva
Saliva was collected in sterile glass jars. Samples were
aliquoted and transferred to 1.5 ml sterile tubes and
stored at -80ºC until use. Total RNA was extracted from
200 μl of saliva using Trizol reagent (Invitrogen, Carlsbad,
CA, USA) following conventional procedures. RNA con-
centration and quality were determined by spectropho-
tometry and visualized by 1% agarose gel electrophoresis
with ethidium bromide.
HCV RNA detection in saliva
HCV-RNA was amplified using a nested reverse
transcription-PCR with the two sets of primers corres-
ponding to the 5′UTR, as reported previously [19,20].
Reverse transcription and the first round of PCR (25-μl re-
actions) were performed using One-Step RT-PCR with
Platinum Taq (Invitrogen). Program parameters were 55°C
for 30 min, 94°C for 2 min, and 40 cycles of 94°C for
30 sec, 56°C for 30 sec, and 72°C for 30 sec. The second
round of PCR (25 μl reactions) was performed using Bio-
Mix (Bioline, London, UK) and 2 μl of first-round PCR
product. Thermal cycler conditions were 94°C for 2 min
and 40 cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C
for 30 sec. The 305 and 251 bp PCR products were ana-
lyzed with 1% agarose gel electrophoresis. This tech-
nique has a detection limit of 50 IU/ml, comparable with
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commercial tests used for qualitative detection of HCV
genome [21,22]. A fragment of the housekeeping gene
cyclophilin was amplified for each sample as internal con-
trol for RNA extraction and RT/PCR reaction, using pri-
mers and conditions previously published [23]. In all
test series, known HCV negative and positive serum
controls were included and the samples were man-
aged with the same precautions during taking, trans-
port and processing.
Determination of serum viral load
Total RNA in serum samples was extracted by an auto-
mated process performed in BioRobot 9604 (Qiagen,
Hilden, Germany) and viral loads were determined by
means of the COBAS Taqman HCV Test v.2.0 (Roche
Molecular Systems, Indianapolis, IN).
HCV detection and genotyping in serum
The HCV RNA in serum samples was extracted using
QIAamp RNA Viral Mini Kit (Qiagen, Valencia, CA) and
was amplified using a nested RT-PCR with the two sets
of primers corresponding to the 5′ UTR, as reported pre-
viously [18,19]. HCV genotype testing was performed
by line probe assay INNO-LiPA version 2.0 (Innogenetics,
Ghent, Belgium).
Data analysis
For continuous variables, averages, frequencies and
percentages were calculated. Univariate analysis was
performed using χ2 or Fisher's exact test to detect in-
dependent variables associated with detection of viral
RNA in saliva. The variables with p values < 0.1 were
introduced in multivariate analysis and, after that,
those with p values <0.05 were considered as independ-
ently associated with viral RNA detection. Pearson’s cor-
relation between MGI and percentage of plaque was also
applied. And to analyze differences between viral loads
was used Mann–Whitney U test. All statistical analysis
was performed using Statgraphics Centurion XV
v. 15.2.06 (Stat Point Technologies, Inc., Virginia, U.S.A.).
Results
The minimal sample size determined was n = 39 pa-
tients. In this study we studied a total of 45 patients, of
which, 19 (42.2%) were male and 26 (57.8%) were female.
Mean age was 45.7 years (95% CI: 42.4–49.0). Twenty one
(46.6%) patients had chronic hepatitis without clinical
signs of cirrhosis, 23 (51.1%) had various grades of cirrho-
sis and one (2.4%) patient presented HCC. Viral load in
serum was in the range of 2.31–6.68 log IU/ml with a
mean of 5.46 log IU/ml (95% CI 5.23–5.70). Prothrombin
time was in the range of 45–104% with a mean of 79%
(95% CI 73–84). Platelet count was in the range of 5 ×
104–3.0 × 105 per mm3 with a mean of 1.55 × 105 per
mm3 (95% CI 1.30 x 105–1.80 x 105) (Table 1). HCV geno-
type was determined in 45 patients included in the study,
17 patients had HCV 1a (37.7%), 20 had 1b (44.4%), 1 had
2a (2.2%), 3 had 2b (6.8%) and 4 had 3a (8.9%) (Table 1).
Four patients presented a good level of dental plaque
(8.9%), but this was just acceptable in 16 (35.6%) and un-
acceptable in 25 (55.6%) patients (Table 2). The degree
of the MGI found in patients with active HCV infec-
tion was as follows: healthy (0.0–0.1) in three (6.7%)
patients, mild (0.2–1.0) in 10 (22.2%) patients, moderate
(1.1–2.0) in seven (15.5%) patients, and severe (>2.0) in 25
(55.6%) patients (Table 2). A positive correlation (r = 0.88,
p = 0.0094) between MGI and dental plaque was found
(Figure 1).
HCVRNA was detected in the saliva of 29 (64.4%)
patients and was not detected in 16 (35.6%) patients
(Table 2). According to univariate analysis, three inde-
pendent variables were associated with the detection of
HCV RNA in saliva: gender, viral load and acceptable
Table 1 Epidemiological characteristics of HCV infected
patients
General characteristics n (%)
Male/female 19 (42.2 )/26 (57.8)
Mean age 45.7 years (95% CI 42.4–49.0 years)
Risk
Blood transfusion 25 (55.5)
Multiple sex partners 6 (13.3)
History of surgery 2 (4.4)
Dental care 1 (2.2)
Intravenous drug user 2 (4.4)
Unidentified source of infection 9 (20)
Liver disease status
Active hepatitis 21 (46.6)
Cirrhosis 23 (51.1)
Hepatocellular carcinoma 1 (2.3)
Laboratory data
Range serum viral load (log IU/ml) 2.31–6.68
Mean serum viral load (log IU/ml) 5.46 (95% CI 5.23–5.70)
Range prothrombin time (%) 45–104
Mean prothrombin time (%) 79 (95% CI 73–84)
Range platelet count (μl) 5.3 × 104–3.0 × 105
Mean platelet count (μl) 1.55 × 105 (1.30 × 105–1.80 × 105)
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level of dental plaque. Indeed, 16/19 men (84.2%) vs.
13/26 women (50%) were positive to HCV in saliva (p =
0.001); 27/31 (87%) patients with a viral load >5.17 log
IU/Ml were positive to HCV in saliva vs. 2/14 (14.3%) pa-
tients with viral load <5.17 log IU/mL (p = 0.0000); and
15/20 (75%) patients with an acceptable level of dental
plaque were positive to HCV in saliva vs. 14/25 (56%) pa-
tients with an unacceptable level of dental plaque (p =
0.07) (Table 3). Univariate analysis also showed that age,
liver disease severity, MGI, prothrombin activity, platelet
counts, and viral genotype were not associated with detec-
tion of HCV RNA in saliva. At respect, salivary HVC was
detected in 15/22 (49%) patients ≤ 45 years old vs. 14/23
(51%) patients >46 years old (p = 0.17); in 13/22 (59%) pa-
tients with cirrhosis vs. 16/23 (69.5%) patients without cir-
rhosis (p = 0.358). There were 9/13 (69.2%) patients with
platelet counts <105/mm3 vs. 20/32 (62.5%) patients with
platelet counts >105/mm3 (p = 0.652). There were 8/12
(66%) patients with activity prothrombin <70% vs. 21/33
(63%) patients with activity prothrombin >70% (p = 0.703).
There were 9/13 (69%) patients with moderate to severe
gingivitis (MGI >1.0) vs. 20/32 patients with healthy gums
(MGI <1.0) (p = 0.66). With respect to HCV genotype 24/
37(64.7%) patients had genotype 1 vs. 5/8(62%) with other
genotype (p =0.484) (Table 3).
The variables with a p value <0.1 were introduced in a
multivariate analysis and only one independent variable,
viral load >5.17 log IU/mL, remained significantly associ-
ated with HCV detection in saliva (p = 0.0002) (Table 3).
To corroborate that viral load was associated with the
presence of HCV in saliva; patients were grouped in the
basis of their positive or negative result of salivary HCV
detection. A statistical difference was observed between
viral load means, log 5.85 IU/mL (95% CI 5.67–6.02) for
patients with HCV in saliva vs. 4.77 IU/mL (95% CI 4.35–
5.19) for patients without HCV in saliva (p = 0.0001)
(Figure 2).
Discussion
In this study we determined the presence of HCV in sal-
iva of patients with active hepatitis C in order to identify
some associated factors. The role of oral cavity fluids in
the transmission of HCV is controversial. Several studies
reported the presence of HCV RNA in saliva, but the
infectivity of salivary HCV particles has not been con-
firmed. Then, there is no solid data supporting that the
presence of HCV in saliva is an effective HCV transmis-
sion route.
In addition, epidemiological studies show the limited
transmission of salivary HCV [4]. Potential sources of
HCV within saliva includes GCF, leukocytes that migrate
through the epithelium to the gingival groove [5], sali-
vary glands [10,11] and peripheral blood mononuclear
cells from bleeding tissues [12]. Therefore, we hypothe-
sized that the presence of periodontal and gingival dis-
ease may be a contributing factor for virus dissemination.
However, in our study and that of others, salivary HCV
has been detected both in patients with healthy and dis-
eased periodontium [5,6,8]. In this regard we did not find
any association between the degree of gingival inflamma-
tion and viral RNA detection in saliva. There was neither
significant difference of salivary HCV between patients
with healthy gums (9/13, 69%) and those with gingival dis-
ease (20/32, 62.5%). It was observed a positive correlation
between MGI and percent plaque (Figure 1), coinciding
with other studies demonstrated that the severity of pe-
riodontal disease varies depending on the quantity and
quality of the presence of biofilm [24]. We found that the
main factor associated with the presence of HCV in saliva
was the high viral load in serum (>5.17 log IU/ml) as
has been found in some other studies [5,7]. In our study,
Table 2 Dental study data and HVC detected in saliva
MGI n (%)
Healthy (0.0–0.1) 3 (6.7)
Mild (0.2–1.0) 10 (22.2)
Moderate (1.1–2.0) 7 (15.5)
Severe (>2.0) 25 (55.6)
Dental plaque (%)
Good (≤20%) 4 (8.9)
Acceptable (20%–40%) 16 (35.6)
Unacceptable (>40%) 25 (55.6)
Salivary HCV
Detected 29 (64.4)
Not detected 16 (35.6)
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Figure 1 The Pearson test was used to show the correlation
between variables. There was a significant positive correlation
between the percentage of plaque and the modified gingival index
(r =0.88; p = 0.0094).
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27/29 (93.1%) patients with viral RNA in saliva had high
viral loads; however, 4/16 (25%) patients with a negative
result in saliva were also within the range of high viral
load (5.17–5.60 log IU/ml).
In our work we determined two other clinical parame-
ters in patients, in order to obtain other data related
with the severity of liver disease. Prothrombine time and
platelets counts are important parameters may be associ-
ated with bleeding of bucal cavity, therefore may be as-
sociated with a higher probability of infection through
saliva, however, none of two parameters was statistically
associated with presence of HCV RNA in saliva.
The prevalence of salivary HCV differed with the source
of the samples, study population, and method of viral
RNA extraction and detection. In our study the prevalence
of HCV in saliva was 64.4% in patients with active infec-
tion. Some studies reported prevalence values of 31–100%
in saliva samples [5,7] and 38–85% in oral and gingival
groove fluid samples [5,8]. Another study reported 52%
of salivary HCV in a group of patients coinfected with
HIV [25].
It is notable that, in our study, 20% of patients had an
unidentifiable source of infection as has been found in
other studies [26,27]. Several epidemiological studies of
HCV performed in Mexican people that included blood
donors, [28-30] open population, [31,32] and patients
with cirrhosis [33] mentioned dental treatment as a
probable risk factor. Other studies found that living with a
family member infected with HCV [34,35] or suffering
from liver disease [33,36,37] was an associated risk factor.
Although it is known that multiple factors contribute to
HCV transmissibility for saliva [5,38] and viral loads are
very low in this [39]. The presence of HCV in saliva is to
draw attention mainly in patients with active infection
and high viral loads, patients who require guidance on
their oral health by dentist. On the other hand there
have been very favorable changes in the practice of in-
fection control procedures among dentists. Although,
not all are well familiar with infection control proce-
dures [40,41]. These results should be interpreted with
caution. Since the domestic nonparenteral transmission
of HCV occurs [42,43], but transmission mechanisms
have not been established.
Conclusion
Detection of HCV in saliva was associated with a rela-
tively high viral load in serum but not with the level of
periodontal disease or liver disease severity.
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Table 3 Factors associated with salivary Hepatitis C Virus detection
Univariate analysis Multivariate analysis
Factor OR (95% CI) p OR (95% CI) p
Gender (male) 9.91 (7.74–12.6) 0.001 _____________ _____
Age (>46 years) 0.53 (0.37–0.54) 0.173 _____________ _____
Cirrhosis 0.56 (0.46–0.67) 0.358 _____________ _____
MGI (>1.0) 1.35 (1.09–1.67) 0.666 _____________ _____
Dental plaque (<40%) 3.21 (2.51–3.99) 0.070 _____________ _____
Serum viral load (>5.17 log IU/ml) 40.5 (30.8–53.0) 0.0000 25 (18.8–32.5) 0.0002
Prothrombin time (<70%) 1.22 (0.98–1.44) 0.703 _____________ _____
Platelet count (<105 mm3) 0.74 (0.61–0.89) 0.652 _____________ _____
Viral genotype 0.54 ( 0.29-0.68) 0.481 _____________ _____
MGI, modified gingival index.
Figure 2 The Mann–Whitney test was used for serum viral
loads comparison of patients with or without salivary HCV RNA
(p = 0.0001). The graph shows the mean and the 95% confidence
interval.
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